Oxford University and Ellison Institute link for AI vaccine research
The University of Oxford has announced the launch of a new vaccine research programme in collaboration with the Ellison Institute…
All articles by RanjithKumar Dharma
RanjithKumar Dharma
-
-
Moderna’s updated Covid-19 vaccine gets Canadian approval
Moderna has secured approval from Health Canada for Spikevax, its updated Covid-19 mRNA vaccine, which targets the SARS-CoV-2 LP.8.1 variant.…
-
Daiichi Sankyo and AstraZeneca’s Datroway receives approval in China
Daiichi Sankyo and AstraZeneca have received approval from China’s National Medical Products Administration (NMPA) for Datroway (datopotamab deruxtecan) to treat…
-
Keros gains FDA orphan drug status for DMD treatment KER-065
Keros Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational therapy KER-065…
-
Boehringer and AnGes link on drug substance manufacture for PAD
Boehringer Ingelheim has entered a contract development and manufacturing agreement for the drug substance of AnGes' investigational therapy targeting peripheral…
-
FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration (FDA) for izalontamab…
-
āshibio licences vantictumab for rare bone disorder
Biotechnology company āshibio has entered an exclusive licencing agreement with Mereo BioPharma for the monoclonal antibody, vantictumab, to treat a…
-
Santen and RemeGen sign licence deal for retinal disease injection
Santen Pharmaceutical has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to…
-
Merck announces EC approval of Ogsiveo for desmoid tumours
The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for Ogsiveo (nirogacestat) to…
-
Aquestive signs $75m agreement for launch of Anaphylm
Aquestive Therapeutics has made a strategic funding agreement worth $75m with RTW Investments to support the potential launch of Anaphylm…